A Bayesian method53 was used to fine-map lung function-associated signals to the set of variants that were 95% likely to contain the underlying causal variant (assuming that the causal variant has been analysed). This was undertaken for novel signals and for previously-reported signals which reached P<10-5 in the stage 1 results. Following van de Bunt et al.54 we set the value of a prior W=0.4 in the approximate Bayes Factor formula. Signals in the HLA were not included.
